Table 1

Data collected at baseline assessment

ClinicalRadiologicalFunctionalHistologyTreatment received
AgeLaryngeal subsiteEORTC QLQ-C30From biopsyPrimary non-surgical treatment
  • Chemotherapy agent and dose

  • Radiotherapy dose and fractionation

Date of birthCartilaginous framework involvementEORTC HN35HistologyPrimary surgical management-procedure performed
Gender at birthMaximum dimensionVocal cord functionGradePostoperative chemotherapy
NHS noExtralaryngeal spreadDIGEST VFSS/FEES scaleDifferentiationPostoperative radiotherapy
Treatment hospitalBilateral involvementPSS-HNDigital photography if availableDate of completion of treatment
GP postcodeTumour max SUVMDADIFrom resection (if performed)
Date of biopsySigns of aspirationVHI-10Digital photography if available
Date of initiation of treatmentCervical lymph node involvement100 mL water swallow testPrimary site
Aim of treatmentEvidence of extra-capsular spreadMaximum phonation timeDimension
TNM stageGRBAS scalePrimary site
Smoking historyVoice recordingUni/multifocal
Alcohol historyHistology
ACE scoreDifferentiation
Clinical frailty scaleInvasiveness
WHO performanceInvasive front
WeightPerineural invasion
Presence of tube feedingLymphovascular invasion
Closest margin
Pathological TNM staging
Neck disease
Total no of nodes dissected
Total no of involved nodes
  • DIGEST, Dynamic Imaging Grade of Swallowing Toxicity; EORTC HN35, European Organization for the Research and Treatment of Cancer Head and Neck Cancer Quality of Life Questionnaire; EORTC QLQ-C30, European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire; FEES, Fiberoptic Endoscopic Evaluation of Swallowing; GP, General Practitioner; GRBAS, Grade, Roughness, Breathiness, Aesthenia, Strain Scale; MDADI, MD Anderson Dysphagia Inventory; NHS, National Health Service; PSS-HN, Performance Status Scale for Head & Neck Cancer Patients; SUV, Standardised Uptake Values; TNM, Tumour, Node, Metastasis; VFSS, Videofluoroscopic Swallow Study; VHI, Voice Handicap Index.